Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0771
    -0.0022 (-0.20%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2619
    -0.0004 (-0.03%)
     
  • USD/JPY

    151.3410
    -0.0310 (-0.02%)
     
  • Bitcoin USD

    69,796.92
    -594.49 (-0.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Bristol-Myers Squibb Reveals Fresh Rheumatoid Arthritis Research And Real-World Data At European Congress Of Rheumatology

Bristol-Myers Squibb Company (NYSE: BMY) revealed Wednesday that it would present fresh data providing insights into the field of rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016) held June 8-11 in London.

Bristol-Myers said that among the studies that would be presented are findings from the first U.S. observational study exploring patients' response to treatment based on their baseline status for two biomarkers of poor prognosis, anti-cyclic citrullinated peptide (anti-CCP, also known as ACPA) and rheumatoid factor (RF).

The company said both anti-CCP and RF were biomarkers of poor prognosis that may be connected with a number of severe disease progression and joint damage. It added that this new study and its results would be featured in an Annual Congress of Rheumatology and in an oral presentation on June 9.

Bristol Myers' Head of Specialty Development, Douglas Manion, commented, "As a leader in the field of immunoscience, Bristol-Myers Squibb is dedicated to the research of disease biomarkers and finding transformative ways that may help reduce the impact of autoimmune diseases like RA."

He continued, "The real-world data from the Corrona RA registry study showed patients who are seropositive for anti-CCP or RF, and particularly those who are double seropositive, were more likely to have incremental improvements in response to Orencia than if they were negative for these biomarkers as compared to those who initiated TNF-inhibitors. In addition, there was differential response to Orencia but not with TNF-inhibitors in patients who were CCP+ vs. CCP-. These findings and scientific insights underscore our decade-long commitment to ongoing Orencia research."

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement